drugset
drugset / Trial / NCT02183090

Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects

NCT02183090 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the pharmacokinetics and tolerability of an intramuscular 15 mg meloxicam injection in comparison to the 15 mg oral tablet

Timeline

Start
1998-11
Primary completion
1998-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meloxicam Small molecule 15 mg Intramuscular

Indications

No indication recorded.